Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
  • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
  • A01N25/22—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing ingredients stabilising the active ingredients
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
  • A01N25/32—Ingredients for reducing the noxious effect of the active substances to organisms other than pests, e.g. toxicity reducing compositions, self-destructing compositions
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
  • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
  • A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
  • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
  • A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
  • A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/10—Anthelmintics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/14—Ectoparasiticides, e.g. scabicides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/61—Halogen atoms or nitro radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
  • C07D239/52—Two oxygen atoms
  • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
  • C07D495/14—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D498/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
  • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
  • C07D513/04—Ortho-condensed systems

Definitions

• This invention relates to certain pyrimidinium compounds, their //-oxides, salts and their compositions suitable for agronomic, nonagronomic and animal health uses, methods of their use for controlling invertebrate pests such as arthropods in both agronomic and nonagronomic environments, and for treatment of parasite infections in animals or infestations in the general environment.
• invertebrate pests The control of invertebrate pests is extremely important in achieving high crop efficiency. Damage by invertebrate pests to growing and stored agronomic crops can cause significant reduction in productivity and thereby result in increased costs to the consumer.
• the control of invertebrate pests in forestry, greenhouse crops, ornamentals, nursery crops, stored food and fiber products, livestock, household, turf, wood products, and public health is also important. Many products are commercially available for these purposes, but the need continues for new compounds that are more effective, less costly, less toxic, environmentally safer or have different sites of action.
• U.S. Patent No. 5,151,427 discloses mesoionic pyrimidinium compounds of Formula i as anthelmintics
• R 1 and R 2 are independently C ⁇ -Cg alkyl
• R 3 is a heteroaromatic 6- membered ring
• R 4 and R 5 are independently hydrogen or Q-C 4 alkyl.
• This invention is directed to compounds of Formula 1 (including all stereoisomers), TV- oxides, and salts thereof, and compositions containing them and their use for controlling invertebrate pests:
• X is O or S
• Y is O or S
• X 1 is O, S or NR 9 ;
• E is O, S or NR 9a ;
• R 3a , R 3 b, R 3c and R 3(1 are independently H, halogen, cyano, hydroxy, amino, nitro,
• N(R 21 )C(O)0R 19 , N(R 21 XX O)NR 21 R 22 , OSO 2 R 18 , OSO 2 NR 21 R 22 ,
• alkylsulfonyl C 3 -C 8 cycloalkylsulf ⁇ nyl, C 3 -C 8 cycloalkylsulfonyl, C 4 -C 10 cycloalkylalkylsulfinyl, C 4 -C 10 cycloalkylalkylsulfonyl, C 2 -C 8 alkenylsulfinyl,
• haloalkylcycloalkyl C 4 -C 8 cycloalkylalkyl, C 4 -C 8 halocycloalkylalkyl, C 1 -Cg alkoxy, C 1 -C 6 haloalkoxy, C 2 -C 6 alkoxycarbonyl, C 2 -C 6 haloalkoxycarbonyl, C 2 -C 6 alkylcarbonyl and C 2 -C 6 haloalkylcarbonyl;
• each R 6 is independently H; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 4 -C 8 alkylcycloalkyl, C 4 -C 8 cycloalkylalkyl, C 6 -C 1Q
• each R 7 and R 8 is independently H; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl,
• each R 9 is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8
• each R 9a is independently H; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 4 -C 8 alkylcycloalkyl, C 4 -C 8 cycloalkylalkyl, C 6 -C 10
• cycloalkylcycloalkyl C 5 -C 10 alkylcycloalkylalkyl, C 3 -C 6 cycloalkenyl, C 2 -C 6 alkylcarbonyl or C 2 -C 6 alkoxycarbonyl, each unsubstituted or substituted with at least one substituent independently selected from the group consisting of halogen, cyano, nitro, CHO, C(O)OH, C(O)NH 2 , C(O)R 10 , C(O)OR 11 , C(O)NR 12 R 13 , OR 11 , S(O) n R 10 , SO 2 NR 12 R 13 and Si(R 10 ) 3 ;
• each R 10 and R 11 is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 4 -C 8 alkylcycloalkyl, C 4 -C 8 cycloalkylalkyl, C 6 -C 10
• cycloalkylcycloalkyl C 5 -C 10 alkylcycloalkylalkyl or C 3 -C 6 cycloalkenyl, each unsubstituted or substituted with at least one substituent independently selected from the group consisting of halogen, cyano, nitro, CHO, C(O)OH, C(O)NH 2 , C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfmyl, C 1 -C 4 alkylsulfonyl, C 1 -C 4 haloalkylthio, C 1 -C 4 haloalkylsulf ⁇ nyl, C 1 -C 4
• haloalkylsulfonyl C 1 -C 4 alkylamino, C 2 -Cg dialkylamino, C 3 -C 6
• NR 21 NR 21 C( X 2 )NR 22 R 23 , NR 21 NR 21 SO 2 NR 22 R 23 , Z 1 Q t or Z 1 QJZ 1 Q t ; or Cl _ C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 10 cycloalkyl, C 4 -C 10 alkylcycloalkyl, C 4 -C 10 cycloalkylalkyl, Cg-C 14 cycloalkylcycloalkyl, C 5 -C 10 alkylcycloalkylalkyl, C 3 -C 8 cycloalkenyl, C 1 -C 8 alkoxy, C 3 -C 8 cycloalkoxy,
• each Q 1 is independently a 3- to 10-membered ring or a 7- to 11-membered ring
• each R 16 is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8
• haloalkylsulfinyl C 1 -C 4 haloalkylsulfonyl, C 1 -C 4 alkylamino, C 2 -C 8 dialkylamino, C 3 -C 6 cycloalkylamino, C 2 -C 4 alkoxyalkyl, C 2 -C 4
• each R 18 , R 19 and R 20 is independently Q t ; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 4 -C 8 alkylcycloalkyl, C 4 -C 8 cycloalkylalkyl, C 6 -
• each R 21 is independently Q t or H; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 4 -C 8 alkylcycloalkyl, C 4 -C 8 cycloalkylalkyl, C 6 -C 10 cycloalkylcycloalkyl, C 5 -C 10 alkylcycloalkylalkyl or C 3 -C 6 cycloalkenyl, each unsubstituted or substituted with at least one substituent independently selected from R 17 ;
• each R 22 and R 23 is independently Q t or H; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 4 -C 8 alkylcycloalkyl, C 4 -C 8 cycloalkylalkyl, C 6 -
• each R 24 is independently H, cyano, OCN, SCN, CHO, C(O)OH, C(O)NH 2 ,
• a 1, 2 or 3;
• each n is independently 0, 1 or 2;
• This invention also provides a composition comprising a compound of Formula 1, an
• this invention also provides a composition for controlling an invertebrate pest comprising a compound of Formula 1, an N-oxide, or a salt thereof, and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, said composition further comprising at least one additional biologically active compound or agent.
• This invention provides a method for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of Formula 1, an N-oxide, or a salt thereof (e.g., as a composition described herein).
• This invention also relates to such method wherein the invertebrate pest or its environment is contacted with a composition comprising a biologically effective amount of a compound of Formula 1, an N-oxide, or a salt thereof, and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, said composition optionally further comprising a biologically effective amount of at least one additional biologically active compound or agent.
• This invention also provides a method for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of any of the aforesaid compositions wherein the environment is a plant.
• This invention also provides a method for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of any of the aforesaid compositions wherein the environment is an animal.
• This invention also provides a method for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of any of the aforesaid compositions wherein the environment is a seed.
• This invention also provides a method for protecting a seed from an invertebrate pest comprising contacting the seed with a biologically effective amount of a compound of
• Formula 1 an JV-oxide, or a salt thereof (e.g., as a composition described herein). This invention also relates to the treated seed.
• Formula 1 an JV-oxide, or a salt thereof, and at least one carrier.
• This invention further provides a method for treating, preventing, inhibiting and/or killing ecto and/or endoparasites comprising administering to and/or on an animal a parasiticidally effective amount of a compound of Formula 1, an JV-oxide, or a salt thereof
• This invention also relates to such method wherein a parasiticidally effective amount of a compound of Formula 1, an JV-oxide, or a salt thereof,
• a composition described herein is administered to an environment (e.g., a stall or blanket) in which an animal resides.
• composition, mixture, process or method that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process or method.
• the term “invertebrate pest” includes arthropods, gastropods and nematodes of economic importance as pests.
• arthropod includes insects, mites, spiders, scorpions, centipedes, millipedes, pill bugs and symphylans.
• gastropod includes snails, slugs and other Stylommatophora.
• nematode refers to a living organism of the Phylum Nematoda.
• helminths includes roundworms, heartworms, phytophagous nematodes (Nematoda), flukes (Tematoda), Acanthocephala and tapeworms (Cestoda).
• invertebrate pest control means inhibition of invertebrate pest development (including mortality, feeding reduction, and/or mating disruption), and related expressions are defined analogously.
• agronomic refers to the production of field crops such as for food and fiber and includes the growth of corn, soybeans and other legumes, rice, cereal (e.g., wheat, oats, barley, rye, rice, maize), leafy vegetables (e.g., lettuce, cabbage, and other cole crops), fruiting vegetables (e.g., tomatoes, pepper, eggplant, crucifers and cucurbits), potatoes, sweet potatoes, grapes, cotton, tree fruits (e.g., pome, stone and citrus), small fruit (berries, cherries) and other specialty crops (e.g., canola, sunflower, olives).
• wheat e.g., wheat, oats, barley, rye, rice, maize
• leafy vegetables e.g., lettuce, cabbage, and other cole crops
• fruiting vegetables e.g., tomatoes, pepper, eggplant, crucifers and cucurbits
• potatoes e.g., sweet potatoes, grapes, cotton, tree fruits (e.g.
• nonagronomic refers to other than field crops, such as horticultural crops (e.g., greenhouse, nursery or ornamental plants not grown in a field), residential, agricultural, commercial and industrial structures, turf (e.g., sod farm, pasture, golf course, lawn, sports field, etc.), wood products, stored product, agro-forestry and vegetation management, public health (i.e. human) and animal health (e.g., domesticated animals such as pets, livestock and poultry, undomesticated animals such as wildlife) applications.
• horticultural crops e.g., greenhouse, nursery or ornamental plants not grown in a field
• turf e.g., sod farm, pasture, golf course, lawn, sports field, etc.
• wood products e.g., stored product, agro-forestry and vegetation management
• public health i.e. human
• animal health e.g., domesticated animals such as pets, livestock and poultry, undomesticated animals such as wildlife
• Nonagronomic applications include protecting an animal from an invertebrate parasitic pest by administering a parasiticidally effective (i.e. biologically effective) amount of a compound of the invention, typically in the form of a composition formulated for veterinary use, to the animal to be protected.
• a parasiticidally effective (i.e. biologically effective) amount of a compound of the invention typically in the form of a composition formulated for veterinary use, to the animal to be protected.
• parasiticidal i.e. biologically effective
• Parasiticidally refers to observable effects on an invertebrate parasite pest to provide protection of an animal from the pest. Parasiticidal effects typically relate to diminishing the occurrence or activity of the target invertebrate parasitic pest.
• Such effects on the pest include necrosis, death, retarded growth, diminished mobility or lessened ability to remain on or in the host animal, reduced feeding and inhibition of reproduction.
• These effects on invertebrate parasite pests provide control (including prevention, reduction or elimination) of parasitic infestation or infection of the animal.
• alkyl used either alone or in compound words such as “haloalkyl” includes straight-chain or branched alkyl, such as, methyl, ethyl, n-propyl, /-propyl, or the different butyl, pentyl or hexyl isomers.
• alkenyl includes straight-chain or branched alkenes such as ethenyl, 1-propenyl, 2-propenyl, and the different butenyl, pentenyl and hexenyl isomers.
• Alkenyl also includes polyenes such as 1 ,2-propadienyl and 2,4-hexadienyl.
• Alkynyl includes straight-chain or branched alkynes such as ethynyl, 1-propynyl, 2-propynyl and the different butynyl, pentynyl and hexynyl isomers. "Alkynyl” can also include moieties comprised of multiple triple bonds such as 2,5-hexadiynyl.
• Cycloalkyl includes, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
• the term “cycloalkylalkyl” denotes cycloalkyl substitution on an alkyl moiety. Examples of “cycloalkylalkyl” include cyclopropylmethyl, cyclopentylethyl, and other cycloalkyl moieties bonded to straight-chain or branched alkyl groups.
• Cycloalkenyl includes groups such as cyclopentenyl and cyclohexenyl as well as groups with more than one double bond such as 1,3- and 1,4-cyclohexadienyl.
• cycloalkoxy denotes cycloalkyl attached to and linked through an oxygen atom such as cyclopentyloxy and cyclohexyloxy.
• Alkylcycloalkylalkyl denotes an alkyl group substituted with alkylcycloalkyl. Examples of “alkylcycloalkylalkyl” include 1-, 2-, 3- or 4-methyl or -ethyl cyclohexylmethyl.
• cycloalkylcycloalkyl denotes cycloalkyl substitution on another cycloalkyl ring, wherein each cycloalkyl ring independently has from 3 to 7 carbon atom ring members.
• cycloalkylcycloalkyl examples include cyclopropylcyclopropyl (such as l,l'-bicyclopropyl-l-yl, l,l'-bicyclopropyl-2-yl), cyclohexylcyclopentyl (such as A- cyclopentylcyclohexyl) and cyclohexylcyclohexyl (such as l,l'-bicyclohexyl-l-yl), and the different cis- and /rans-cycloalkylcycloalkyl isomers, (such as (li?,25)-l,l'-bicyclopropyl-2- yl and (li?,2i?)-l,l'-bicyclopropyl-2-yl).
• cyclopropylcyclopropyl such as l,l'-bicyclopropyl-l-yl, l,l'-bicyclopropyl-2
• Cycloalkylamino denotes an NH radical substituted with cycloalkyl.
• Examples of “cycloalkylamino” include cyclopropylamino and cyclohexylamino.
• the term “cycloalkylaminoalkyl” denotes cycloalkylamino substitution on an alkyl group.
• Examples of “cycloalkylaminoalkyl” include cyclopropylaminomethyl, cyclopentylaminoethyl, and other cycloalkylamino moieties bonded to straight-chain or branched alkyl groups.
• halogen either alone or in compound words such as “haloalkyl”, or when used in descriptions such as “alkyl substituted with halogen” includes fluorine, chlorine, bromine or iodine. Further, when used in compound words such as “haloalkyl”, or when used in descriptions such as “alkyl substituted with halogen” said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Examples of “haloalkyl” or “alkyl substituted with halogen” include CF 3 , CH 2 Cl, CH 2 CF 3 and CCl 2 CF 3 .
• haloalkenyl is defined analogously to the term “haloalkyl”.
• haloalkynyl include HC ⁇ CCHCl, CF 3 C ⁇ C, CC1 3 C ⁇ C and FCH 2 C ⁇ CCH 2 .
• haloalkoxy examples include CF 3 O, CCl 3 CH 2 O, HCF 2 CH 2 CH 2 O and CF 3 CH 2 O.
• haloalkylthio examples include CCl 3 S, CF 3 S, CCl 3 CH 2 S and ClCH 2 CH 2 CH 2 S.
• haloalkylamino examples include CF 3 (CH 3 )CHNH, (CF 3 ) 2 CHNH and CH 2 ClCH 2 NH.
• halocycloalkyl examples include 2-chlorocyclopropyl, 2-fluorocyclobutyl, 3-bromocyclopentyl and 4-chlorocyclohexyl.
• halodialkyl either alone or in compound words such as “halodialkylamino" means at least one of the two alkyl groups is substituted with at least one halogen atom, and independently each halogenated alkyl group may be partially or fully substituted with halogen atoms which may be the same or different.
• halodialkylamino include (BrCH 2 CH 2 ) 2 N and BrCH 2 CH 2 (ClCH 2 CH 2 )N.
• Alkoxy includes, for example, methoxy, ethoxy, n-propoxy, isopropoxy and the different butoxy, pentoxy and hexyloxy isomers.
• Alkoxyalkyl denotes alkoxy substitution on alkyl. Examples of “alkoxyalkyl” include CH 2 OCH 3 , CH 2 CH 2 OCH 3 , CH 2 OCH 2 CH 3 , CH 2 OCH 2 CH 2 CH 2 CH 3 and CH 2 CH 2 OCH 2 CH 3 .
• alkynyloxy includes straight-chain or branched alkynyloxy moieties. Examples of “alkynyloxy” include HC ⁇ CCH 2 0, CH 3 C ⁇ CCH 2 O and CH 3 C ⁇ CCH 2 CH 2 O.
• alkylthio includes straight-chain or branched alkylthio moieties such as methylthio, ethylthio, and the different propylthio, butylthio, pentylthio and hexylthio isomers.
• Alkylsulfinyl includes both enantiomers of an alkylsulfinyl group.
• Alkylamino denotes an NH radical substituted with straight-chain or branched alkyl.
• alkylamino examples include NHCH 2 CH 3 , NHCH 2 CH 2 CH 3 , and NHCH 2 CH(CH 3 ) 2 .
• Dialkylamino denotes an N radical substituted independently with two straight-chain or branched alkyl groups. Examples of “dialkylamino” include N(CH 3 ) 2 , N(CH 3 CH 2 CH 2 ) 2 and N(CH 3 )CH 2 CH 3 .
• Halodialkylamino denotes one straight-chain or branched alkyl moiety and one straight-chain or branched haloalkyl moiety bonded to an N radical, or two independent straight-chain or branched haloalkyl moieties bonded to an N radical, wherein “haloalkyl” is as defined above.
• Examples of “halodialkylamino” include
• Alkylcarbonyl denotes a straight-chain or branched alkyl moiety bonded to a C(O) moiety.
• alkylcarbonyl include C(O)CH 3 , C(O)CH 2 CH 2 CH 3 and C(O)CH(CH 3 ) 2 .
• haloalkylcarbonyl include C(O)CF 3 , C(O)CCl 3 , C(O)CH 2 CF 3 and C(O)CF 2 CF 3 .
• Alkoxycarbonyl denotes a straight-chain or branched alkyl moiety bonded to a CO 2 moiety.
• alkoxycarbonyl include C(O)OCH 3 , C(O)OCH 2 CH 3 , C(O)OCH 2 CH 2 CH 3 and C(O)OCH(CH 3 ) 2 .
• Alkylaminocarbonyl denotes a straight-chain or branched alkyl moiety bonded to a C(O)NH moiety.
• the chemical abbreviations C(O)NH, and C(O)N as used herein represent an amide moiety (i.e. an aminocarbonyl group).
• alkylaminocarbonyl include C(O)NHCH 3 , C(O)NHCH 2 CH 2 CH 3 and C(O)NHCH(CH 3 ) 2 .
• Dialkylaminocarbonyl denotes two independent straight-chain or branched alkyl moieties bonded to a C(O)N moiety.
• dialkylaminocarbonyl include C(O)N(CH 3 ) 2 and
• Trialkylsilyl includes 3 branched and/or straight-chain alkyl radicals attached to and linked through a silicon atom, such as trimethylsilyl, triethylsilyl and tert-butyldimethylsilyl.
• C 1 -C 4 alkyl designates methyl through butyl
• C 2 alkoxyalkyl designates CH 2 OCH 3
• C 3 alkoxyalkyl designates, for example, CH 3 CH(OCH 3 ), CH 2 CH 2 OCH 3 or CH 2 OCH 2 CH 3
• C 4 alkoxyalkyl designates the various isomers of an alkyl group substituted with an alkoxy group containing a total of four carbon atoms, examples including CH 2 OCH 2 CH 2 CH 3 and CH 2 CH 2 OCH 2 CH 3 .
• ring or “ring system” as a component of Formula 1 is carbocyclic or heterocyclic.
• ring system denotes two or more connected rings.
• bicyclic ring system denotes a ring system consisting of two rings sharing two or more common atoms.
• a ring or a bicyclic ring system can be part of an extended ring system containing more than two rings wherein substituents on the ring or bicyclic ring system are taken together to form the additional rings, which may be in bicyclic relationships with other rings in the extended ring system.
• aromatic indicates that each of the ring atoms is essentially in the same plane and has ap- orbital perpendicular to the ring plane, and that (4n + T) ⁇ electrons, where n is a positive integer, are associated with the ring or ring system to comply with H ⁇ ckel's rule.
• Partially saturated and “partially unsaturated” with reference to a ring or ring system means that the ring or ring system contains at least one double bond but the ring or ring system is not aromatic.
• a ring system is aromatic if at least one component ring is aromatic.
• carbocyclic ring denotes a ring wherein the atoms forming the ring backbone are selected only from carbon. Unless otherwise indicated, a carbocyclic ring can be a saturated, partially unsaturated, or fully unsaturated ring. When a fully unsaturated carbocyclic ring satisfies H ⁇ ckel's rule, then said ring is also called an "aromatic ring". "Saturated carbocyclic ring” refers to a ring having a backbone consisting of carbon atoms linked to one another by single bonds; unless otherwise specified, the remaining carbon valences are occupied by hydrogen atoms.
• heterocyclic ring or “heterocycle” denotes a ring wherein at least one of the atoms forming the ring backbone is other than carbon. Unless otherwise indicated, a heterocyclic ring can be a saturated, partially unsaturated, or fully unsaturated ring.
• saturated heterocyclic ring refers to a heterocyclic ring containing only single bonds between ring members.
• Partially saturated heterocyclic ring refers a heterocyclic ring containing at least one double bond but which is not aromatic.
• heteroheteroaromatic ring denotes a fully unsaturated aromatic ring in which at least one atom forming the ring backbone is not carbon.
• heteroaromatic ring typically contains no more than 4 nitrogens, no more than 1 oxygen and no more than 1 sulfur. Unless otherwise indicated, heteroaromatic rings can be attached through any available carbon or nitrogen by replacement of a hydrogen on said carbon or nitrogen.
• heteroaromatic bicyclic ring system denotes a ring system consisting of two fused rings, in which at least one of the two rings is a heteroaromatic ring as defined above.
• radical e.g., a 3- to 10-membered ring in the definition of R 1
• the radical may be unsubstituted or substituted with a number of substituents ranging up to the high number stated (e.g., "5"), and the attached substituents are independently selected from the substituents listed.
• a substituent e.g., R 1
• R 1 When a substituent (e.g., R 1 ) is a ring or ring system, it can be attached to the remainder of Formula 1 through any available ring member, unless otherwise described.
• the ring members selected from up to 2 O, up to 2 S and up to 4 N are optional, because the number of heteroatom ring members may be zero.
• the ring or ring system is carbocyclic. If at least one heteroatom ring member is present, the ring or ring system is heterocyclic.
• the nitrogen atom ring members may be oxidized as iV-oxides, because compounds relating to Formula 1 also include iV-oxide derivatives.
• R 14 substituents are optional, 0 to 5 substituents may be present, limited only by the number of available points of attachment.
• unsubstituted in connection with a group such as a ring or ring system means the group does not have any substituents other than its one or more attachments to the remainder of Formula 1.
• optionally substituted means that the number of substituents can be zero. Unless otherwise indicated, optionally substituted groups may be substituted with as many optional substituents as can be accommodated by replacing a hydrogen atom with a non-hydrogen substituent on any available carbon or nitrogen atom. Commonly, the number of optional substituents (when present) ranges from 1 to 3.
• the number of optional substituents may be restricted by an expressed limitation.
• the phrase "optionally substituted with up to 5 substituents independently selected from R 15 " means that 0, 1, 2, 3, 4 or 5 substituents can be present (if the number of potential connection points allows).
• a range specified for the number of substituents exceeds the number of positions available for substituents on a ring, the actual higher end of the range is recognized to be the number of available positions.
• the number of optional substituents is not restricted by an expressed limitation (e.g., the phrases "optionally substituted with halogen” or “unsubstituted or substituted with at least one substituent independently selected from”), it is understood to mean that the number of optional substituents can range from 0 up to the number of positions available.
• substituents such as halogen can be present at every available position (for example, the C 2 F 5 substituent is a C 2 alkyl group substituted with the maximum number of 5 fluorine atoms)
• practical factors such as cost and synthetic accessibility can limit the number of occurences of other substituents.
• These limitations are part of the general synthetic knowledge known to those skilled in the art.
• the number of optional substituents is up to 3 (i.e. 0, 1, 2 or 3) if accommodated by the number of available positions.
• substituents such as R 1 can be (among others) a 5- or 6-membered heteroaromatic ring, optionally substituted with one or more substituents selected from a group of substituents as defined in the Summary of Invention.
• substituents such as R 1 can be (among others) a 5- or 6-membered heteroaromatic ring, optionally substituted with one or more substituents selected from a group of substituents as defined in the Summary of Invention.
• Examples of a 5- or 6-membered heteroaromatic ring optionally substituted with one or more substituents include the rings U-2 through U-61 illustrated in Exhibit 1 wherein R v is any substituent as defined in the Summary of the Invention (e.g., for R 1 ) and r is an integer from 0 to 5, limited by the number of available positions on each U group.
• U-29, U-30, U-36, U-37, U-38, U-39, U-40, U-41, U-42 and U-43 have only one available position, for these U groups r is limited to the integers 0 or 1 , and r being 0 means that the U group is unsubstituted and a hydrogen is present at the position indicated by (R v ) r .
• substituents such as R 1 can be (among others) an 8-, 9- or 10-membered heteroaromatic bicyclic ring system optionally substituted with up to 5 substituents selected from a group of substituents as defined in the Summary of Invention.
• substituents such as R 1 can be (among others) an 8-, 9- or 10-membered heteroaromatic bicyclic ring system optionally substituted with up to 5 substituents selected from a group of substituents as defined in the Summary of Invention.
• Examples of an 8-, 9- or 10-membered heteroaromatic bicyclic ring system optionally substituted with up to 5 substituents include the ring systems H-I through H-23 illustrated in Exhibit 2 wherein R v is any substituent as defined in the Summary of the Invention (e.g., for R 1 ) and r is an integer from 0 to 5, limited by the number of available positions on each H group.
• R v groups are shown in the structures U-I through U-61 and H-I through H-23, it is noted that they do not need to be present since they are optional substituents.
• the nitrogen atoms that require substitution to fill their valence are substituted with H or R v .
• (R v ) r can be attached to any available carbon atom or nitrogen atom of the U or H group.
• the U or H group can be attached to the remainder of Formula 1 through any available carbon or nitrogen of the U or H group by replacement of a hydrogen atom.
• the compounds of Formula 1 are mesoionic inner salts.
• Inner salts also known in the art as “zwitterions” are electrically neutral molecules but carry formal positive and negative charges on different atoms in each valence bond structure according to valence bond theory.
• molecular structure of the compounds of Formula 1 can be represented by the six valence bond structures shown below, each placing the formal positive and negative charges on different atoms. Because of this resonance, the compounds of Formula 1 are also described as "mesoionic”.
• the molecular structure of Formula 1 is depicted as a single valence bond structure herein, this particular valence bond structure is to be understood as representative of all six valence bond structures relevant to bonding in molecules of compounds of Formula 1. Therefore reference to Formula 1 herein relates to all six applicable valence bond structures and other (e.g., molecular orbital theory) structures unless otherwise specified.
• Compounds of this invention can exist as one or more stereoisomers.
• the various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers.
• one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich, and/or to selectively prepare said stereoisomers.
• the compounds of the invention may be present as a mixture of stereoisomers, individual stereoisomers or as an optically active form.
• Compounds of this invention can exist as one or more conformational isomers due to restricted bond rotation caused by steric hinderance.
• a compound of Formula 1 wherein Z is a direct bond and R 1 is phenyl substituted in the ortho-position with a sterically demanding alkyl group (e.g., isopropyl) may exist as two rotamers due to restricted rotation about the R i -pyrimidinium ring bond.
• This invention comprises mixtures of conformational isomers.
• this invention includes compounds that are enriched in one conformer relative to others.
• Non-crystalline forms include embodiments which are solids such as waxes and gums as well as embodiments which are liquids such as solutions and melts.
• Crystalline forms include embodiments which represent essentially a single crystal type and embodiments which represent a mixture of polymorphs (i.e. different crystalline types).
• polymorph refers to a particular crystalline form of a chemical compound that can crystallize in different crystalline forms, these forms having different arrangements and/or conformations of the molecules in the crystal lattice.
• polymorphs can have the same chemical composition, they can also differ in composition due to the presence or absence of co- crystallized water or other molecules, which can be weakly or strongly bound in the lattice. Polymorphs can differ in such chemical, physical and biological properties as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspensibility, dissolution rate and biological availability.
• a polymorph of a compound represented by Formula 1 can exhibit beneficial effects (e.g., suitability for preparation of useful formulations, improved biological performance) relative to another polymorph or a mixture of polymorphs of the same compound represented by Formula 1.
• Preparation and isolation of a particular polymorph of a compound represented by Formula 1 can be achieved by methods known to those skilled in the art including, for example, crystallization using selected solvents and temperatures.
• salts of chemical compounds are in equilibrium with their corresponding nonsalt forms, salts share the biological utility of the nonsalt forms.
• salts of the compounds of Formula 1 are useful for control of invertebrate pests and animal parasites (i.e. are suitable for animal health use).
• the salts of the compounds of Formula 1 include acid-addition salts with inorganic or organic acids such as hydrobromic, hydrochloric, nitric, phosphoric, sulfuric, acetic, butyric, fumaric, lactic, maleic, malonic, oxalic, propionic, salicylic, tartaric, 4-toluenesulfonic or valeric acids.
• inorganic or organic acids such as hydrobromic, hydrochloric, nitric, phosphoric, sulfuric, acetic, butyric, fumaric, lactic, maleic, malonic, oxalic, propionic, salicylic, tartaric, 4-toluenesulfonic or valeric acids.
• salts also include those formed with organic or inorganic bases such as pyridine, triethylamine or ammonia, or amides, hydrides, hydroxides or carbonates of sodium, potassium, lithium, calcium, magnesium or barium. Accordingly, the present
• Embodiments of the present invention as described in the Summary of the Invention include those described below.
• Formula 1 includes stereoisomers, iV-oxides, and salts thereof, and reference to "a compound of Formula 1" includes the definitions of substituents specified in the Summary of the Invention unless further defined in the Embodiments.
• R 3a , R 3 ⁇ when taken alone, and R 3c when taken alone are H or halogen is equivalent to three Embodiments reciting: "R 3a is H or halogen", “R 3 ⁇ when taken alone is H or halogen”, and “R 3c when taken alone is H or halogen", each of which can be independently used as basis to amend or add claims.
• Embodiment 1 A compound of Formula 1 wherein X is O.
• Embodiment 2 A compound of Formula 1 wherein X is S.
• Embodiment 3 A compound of Formula 1 or Embodiments 1 or 2 wherein Y is O.
• Embodiment 4 A compound of Formula 1 or Embodiments 1 or 2 wherein Y is S.
• Embodiment 5 A compound of Formula 1 or any one of Embodiments 1-4 wherein A is
• Embodiment 5c A compound of Embodiment 5a wherein A is S.
• Embodiment 5e A compound of Embodiment 5d wherein A is NR 3e .
• Embodiment 6 A compound of Formula 1 or any one of Embodiments 1— 5b wherein independently R 3a when taken alone (i.e. when R 3a is not taken together with R 3 ⁇ to form a ring), R 3 ⁇ when taken alone (i.e. when R 3 ⁇ is not taken together with R 3a , R 3c or R 3e to form a ring), R 3c when taken alone (i.e. when R 3c is not taken together with R 3 ⁇ or R 3(1 to form a ring) and R 3(1 when taken alone (i.e.
• cycloalkylalkylsulfonyl C 2 -C 8 alkenylthio or C 2 -C 8 alkynylthio, each unsubstituted or substituted with at least one substituent independently selected from R 17 .
• Embodiment 6b A compound of Embodiment 6a wherein independently R 3a when
• Embodiment 6c A compound of Embodiment 6b wherein independently R 3a when taken alone, R 3 ⁇ when taken alone, R 3c when taken alone and R 3 ⁇ when taken alone are H or halogen; or C 1 -C 8 alkyl, C 3 -C 10 cycloalkyl or C 1 -C 8 alkoxy, each optionally substituted with halogen.
• Embodiment 6d A compound of Embodiment 6c wherein independently R 3a when taken alone, R 3 ⁇ when taken alone, and R 3c when taken alone are H or halogen.
• Embodiment 6e A compound of Embodiment 6d wherein independently R 3a when taken alone, R 3 ⁇ when taken alone and R 3c when taken alone are H.
• Embodiment 7 A compound of Formula 1 or any one of Embodiments l-6e wherein
• R 3 d w hen taken alone is H, halogen, C 1 -C 8 alkyl or C 1 -C 8 alkoxy.
• Embodiment 7a A compound of Embodiment 7 wherein R 3 ⁇ when taken alone is halogen, C 1 -C 8 alkyl or C 1 -C 8 alkoxy.
• Embodiment 7a A compound of Formula 1 or any one of Embodiments l-6e wherein
• R 3 d w hen taken alone is halogen, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 8 haloalkyl or C 1 -C 8 haloalkoxy.
• Embodiment 7b A compound of Embodiment 7a wherein R 3 ⁇ when taken alone is halogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxy.
• Embodiment 7c A compound of Embodiment 7b wherein R 3 ⁇ when taken alone is F,
• Embodiment 7d A compound of Embodiment 7c wherein R 3 ⁇ when taken alone is
• Embodiment 7e A compound of Embodiment 7 wherein R 3 ⁇ when taken alone is H, halogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxy.
• Embodiment 7f A compound of Embodiment 7e wherein R 3 ⁇ when taken alone is H or halogen.
• Embodiment 7g A compound of Embodiment 7e wherein R 3 ⁇ when taken alone is H,
• Embodiment 8 A compound of Formula 1 or any one of Embodiments l-7g wherein
• R 3c and R 3 d are taken alone.
• Embodiment 9 A compound of Formula 1 or any one of Embodiments l-7g wherein when R 3c and R 3 ⁇ are taken together with the adjacent carbon atoms to which they are attached to form a 5- or 6-membered ring (which is understood to be optionally substituted with the substituents described in the Summary of the
• Embodiment 9a A compound of Embodiment 9 wherein the 5- or 6-membered ring formed is aromatic.
• Embodiment 9b. A compound of Embodiment 9a wherein the 5- or 6-membered ring formed is 6-membered and carbocyclic (i.e. a fused benzene ring optionally substituted as described in Embodiment 9).
• Embodiment 9d A compound of Embodiment 9 wherein the 5- or 6-membered ring formed is partially unsaturated (and carbocyclic or heterocyclic).
• Embodiment 9e A compound of Formula 1 or any one of Embodiments l-7g and 9-9d wherein R 3c and R 3(1 are taken together with the carbon atoms to which they are attached to form a ring (which is optionally substituted as described in
• Embodiment 10 A compound of Formula 1 or any one of Embodiments 1— 9d wherein
• Embodiment 10b A compound of Embodiment 10a wherein R 3e when taken alone is
• Embodiment 10c A compound of Embodiment 10b wherein R 3e when taken alone is H or C 1 -C 4 alkyl.
• Embodiment 1Od A compound of Embodiment 10c wherein R 3e when taken alone is C 1 -C 4 alkyl.
• Embodiment 1Oe A compound of Embodiment 1Od wherein R 3e when taken alone is CH 3 .
• Embodiment 1Of A compound of Embodiment 10c wherein R 3e when taken alone is H
• Embodiment 1Og A compound of Embodiment 1Of wherein R 3e when taken alone is H.
• Embodiment 11 A compound of Formula 1 or any one of Embodiments 1-10 wherein instances of R 17 in the definition of R 3e are independently selected from R 17a ; R 17a is halogen, OR 11 or Z la Q*; and Z la is a direct bond.
• Embodiment 12 A compound of Formula 1 or any one of Embodiments 1-11 wherein
• R 3 ⁇ and R 3e are taken alone (i.e. R 3 ⁇ and R 3e are not taken together to form a ring).
• Embodiment 13 A compound of Formula 1 or any one of Embodiments 1-11 wherein when R 3e and R 3 ⁇ are taken together with the adjacent carbon atoms to which they are attached to form a 5- or 6-membered ring (which is understood to be optionally substituted with the substituents described in the Summary of the
• Embodiment 14 A compound of Embodiment 13 wherein the 5- or 6-membered ring formed is a fused pyridine ring (which is optionally substituted as described in
• Embodiment 15e A compound of Embodiment 15b wherein Z is a direct bond.
• Embodiment 16 A compound of Formula 1 or any one of Embodiments 1-15d wherein
• X 1 is O or S.
• Embodiment 16a A compound of Formula 1 or any one of Embodiments 1-15d
• X 1 is NR 9 .
• Embodiment 16b A compound of Embodiment 16 wherein X 1 is O.
• Embodiment 16c A compound of Embodiment 16 wherein X 1 is S.
• Embodiment 17 A compound of Formula 1 or any one of Embodiments 1-15c wherein
• Embodiment 17a A compound of Formula 1 or any one of Embodiments 1-15c wherein
• Embodiment 17b A compound of Formula 1 or any one of Embodiments 1-15c
• E is NR 9a .
• Embodiment 18 A compound of Formula 1 or any one of Embodiments 1-15d and 16a wherein each R 9 is independently C 1 -C 6 alkyl, C 2 -C 6 alkylcarbonyl or C 2 -C 6 alkoxycarbonyl.
• Embodiment 18a A compound of Embodiment 18 wherein each R 9 is independently
• Embodiment 19 A compound of Formula 1 or any one of Embodiments 1-15c, 16-16c and 17b wherein each R 9a is independently H, C 1 -C 6 alkyl, C 2 -C 6 alkylcarbonyl or C 2 -C 6 alkoxycarbonyl.
• each ring or ring system optionally substituted with up to 5 substituents independently selected from R 14 .
• Embodiment 20b A compound of Embodiment 20a wherein R 1 is H, halogen or CHO; or C 1 -C 8 alkyl unsubstituted or substituted with at least one substituent independently selected from the group consisting of halogen and Z 1 Q 1 ; or C 2 -C 8 alkenyl or C 2 -C 8 alkynyl, each unsubstituted or substituted with at least one substituent independently selected from the group consisting of halogen, cyano, nitro, CHO, C(O)OH, C(O)NH 2 , C(O)R 10 , C(O)OR 11 , C(O)NR 12 R 13 , OR 11 , S(O) n R 10 , SO 2 NR 12 R 13 , Si(R 10 ) 3 and Z 1 Q t ; or a 3- to 10-membered ring or a 7- to 11-membered ring system, each ring or ring system containing ring members selected from carbon
• Embodiment 20c A compound of Formula 1 or any one of Embodiments 1-2Ob
• instances of Z 1 Q 1 in the definition of R 1 are independently selected from ZlbQtt> w h ereui jVo i s a direct bond; and Q* is a 5- or 6-membered carbocyclic or heterocyclic ring unsubstituted or substituted with at least one substituent independently selected from the group consisting of halogen, C ⁇ -C 4 alkyl, C ⁇ - C 4 haloalkyl, C ⁇ C 4 alkoxy, C ⁇ C 4 haloalkoxy, C ⁇ C 4 alkylthio, C ⁇ C 4 haloalkylthio, Q-C 4 alkylsulfinyl and C ⁇ -C 4 haloalkylsulfinyl.
• Embodiment 21 A compound of Embodiment 20b wherein R 1 is C ⁇ -Cg alkyl optionally substituted with halogen; or a 3- to 10-membered ring or a 7- to 11-membered ring system, each ring or ring system containing ring members selected from carbon atoms and up to 4 heteroatoms independently selected from up to 2 O, up to 2 S, and up to 4 N, wherein up to 3 carbon atom ring members are
• Embodiment 21b A compound of Formula 1 or any one of Embodiments 1-2 Ia
• R 1 wherein the ring or ring system of R 1 is partially unsaturated or aromatic (including heteroaromatic).
• Embodiment 21c A compound of Embodiment 21b wherein the ring or ring system of R 1 is aromatic (including heteroaromatic).
• Embodiment 2 Id A compound of Formula 1 or any one of Embodiments 1-2 Ic wherein the ring system of R 1 is bicyclic.
• Embodiment 22 A compound of Formula 1 or any one of Embodiments 1-2 Ic wherein
• Embodiment 22a A compound of Embodiment 22 wherein the ring of R 1 is 5- or 6- membered.
• Embodiment 22b A compound of Embodiment 22 or 22a wherein the ring of R 1 is carbocyclic.
• Embodiment 22c A compound of Embodiment 22 or 22a wherein the ring of R 1 is heterocyclic.
• Embodiment 22d A compound of Embodiment 22a wherein the ring is phenyl
• R 14 optionally substituted with up to 5 substituents independently selected from R 14 ; a 5-membered heterocyclic ring optionally substituted with up to 3 substituents independently selected from R 14 ; or a 6-membered heterocyclic ring optionally substituted with up to 5 substituents independently selected from R 14 .
• Embodiment 22e A compound of Embodiment 22d wherein R 1 is phenyl optionally substituted with up to 5 substituents independently selected from R 14 ; or pyridinyl optionally substituted with up to 4 substituents independently selected from R 14 .
• Embodiment 22f A compound of Embodiment 22e wherein R 1 is phenyl optionally substituted with up to 3 substituents independently selected from R 14 ; or pyridinyl optionally substituted with up to 2 substituents independently selected from R 14 .
• Embodiment 22g A compound of Embodiment 22f wherein R 1 is phenyl optionally substituted with up to 3 substituents independently selected from R 14 .
• Embodiment 22h A compound of Embodiment 22f wherein R 1 is pyridinyl optionally substituted with up to 2 substituents independently selected from R 14 .
• Embodiment 22i A compound of Formula 1 or any one of Embodiments l-22h
• R 14 when taken alone is halogen, cyano, SF 5 , CHO,
• cycloalkylalkoxy C 2 -C 8 alkenyloxy, C 2 -C 8 alkynyloxy, C 1 -C 8 alkylthio, C 1 - C 8 alkylsulf ⁇ nyl, C 1 -C 8 alkylsulfonyl, C 3 -C 8 cycloalkylthio, C 4 -C 10
• R 17a is halogen, OR 11 or Z 1 Ql
• Embodiment 22j A compound of Embodiment 22i wherein R 14 when taken alone is halogen or Z 1 Q 1 ; or C 1 -C 8 alkyl, C 1 -C 8 alkoxy or C 1 -C 8 alkylthio, each optionally substituted with halogen.
• Embodiment 22k A compound of Formula 1 or any one of Embodiments l-22j
• each instance of R 14 is taken alone (i.e. not taken together with another instance of R 14 on an adjacent ring atom to form a ring).
• Embodiment 22m A compound of Formula 1 or any one of Embodiments l-22d
• R 1 is phenyl or a 6-membered heteroaromatic ring, each optionally substituted with up to 3 substituents independently selected from R 14 .
• Embodiment 22ml A compound of Formula 1 or any one of Embodiments l-22d
• R 1 is phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with up to 3 substituents independently selected from R 14 .
• Embodiment 22n A compound of Embodiment 22m wherein R 1 is phenyl or pyridinyl, each optionally substituted with up to 3 substituents independently selected from
• Embodiment 22p A compound of Embodiment 22o wherein R 21 is C 1 -C 4 alkyl.
• Embodiment 22q A compound of Embodiment 22o wherein R 22 is C 1 -C 4 alkyl.
• Embodiment 22 r A compound of Embodiment 22o wherein one R 14 is Z 1 Q*; Z 1 is a direct bond; and Q 1 is phenyl, pyridinyl or pyrimidinyl, each optionally substituted with up to 5 substituents independently selected from the group consisting of halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy and C 1 -C 4 haloalkoxy.
• alkynylsulfonyl each unsubstituted or substituted with at least one substituent independently selected from the group consisting of halogen, cyano, nitro, CHO,
• Embodiment 23a A compound of Embodiment 23 wherein R 2 is H, halogen, cyano,
• Embodiment 23b A compound of Embodiment 23a wherein R 2 is H.
• Embodiment 23c A compound of Embodiment 23a wherein R 2 is halogen.
• Embodiment 23d A compound of Embodiment 23a wherein R 2 is cyano, CHO,
• Embodiment 23e A compound of Embodiment 23d wherein R 2 is C(O)OR 18 ; or C 1 -
• Embodiment 23 f A compound of Formula 1 or any one of Embodiments l-23e
• R 18a is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 4 -C 8 alkylcycloalkyl, C 4 -C 8 cycloalkylalkyl, C 6 -C 10
• cycloalkylcycloalkyl C 5 -Q 0 alkylcycloalkylalkyl or C 3 -C 6 cycloalkenyl, each unsubstituted or substituted with at least one substituent independently selected from R 17a ;
• R 17a is halogen, OR 11 or Z 1C Q 1 ; and Z lc is a direct bond.
• Embodiment 24a A compound of Embodiment 24 wherein R 2 is a 3- to 10-membered ring containing ring members selected from carbon atoms and up to 4
• heteroatoms independently selected from up to 2 O, up to 2 S, and up to 4 N, wherein up to 3 carbon atom ring members are independently selected from
• Embodiment 24b A compound of Embodiment 24a wherein the ring of R 2 is 5- or 6- membered.
• Embodiment 24c A compound of Embodiment 24b wherein the ring of R 2 is 5- membered and optionally substituted with up to 3 substituents independently selected from R 15 .
• Embodiment 24d A compound of Embodiment 24b wherein the ring of R 2 is 6- membered.
• Embodiment 24e A compound of Formula 1 or any one of Embodiments l-24d
• Embodiment 24f A compound of Embodiment 24e wherein the ring or ring system of
• R 2 is aromatic (including heteroaromatic).
• Embodiment 24h A compound of Formula 1 or any one of Embodiments l-24f
• R 2 wherein the ring or ring system of R 2 is carbocyclic.
• Embodiment 24i A compound of Formula 1 or any one of Embodiments l-24f wherein the ring or ring system of R 2 is heterocyclic.
• Embodiment 25 a A compound of Embodiment 24i wherein R 2 is pyridinyl,
• Embodiment 25b A compound of Embodiment 25 wherein R 2 is pyridinyl, pyrimidinyl or thiazolyl, each optionally substituted with up to 3 substituents independently selected from the group consisting of halogen and C 1 -C 4 alkyl.
• Embodiment 25c A compound of Embodiment 25b wherein R 2 is pyridinyl optionally substituted with at least one substituent independently selected from the group consisting of halogen and C 1 -C 4 alkyl.
• Embodiment 25 d A compound of Embodiment 25 c wherein R 2 is pyridinyl optionally substituted with halogen.
• Embodiment 25e A compound of Embodiment 25d wherein R 2 is pyridinyl optionally substituted with Cl.
• Embodiment 25f A compound of Embodiment 25e wherein R 2 is 6-chloro-3-pyridinyl.
• Embodiment 26 A compound of Embodiment 25b wherein R 2 is thiazolyl optionally substituted with at least one substituent independently selected from the group consisting of halogen or C 1 -C 4 alkyl.
• Embodiment 26a A compound of Embodiment 26 wherein R 2 is thiazolyl optionally substituted with halogen.
• Embodiment 26b A compound of Embodiment 26a wherein R 2 is thiazolyl optionally substituted with Cl.
• Embodiment 26c A compound of Embodiment 26b wherein R 2 is 2-chloro-5-thiazolyl.
• Embodiment 26d A compound of Embodiment 25b wherein R 2 is pyrimidinyl
• Embodiment 26e A compound of Embodiment 24i wherein R 2 is JV-methyl pyrazolyl optionally substituted with C 1 -C 4 alkyl.
• Embodiment 26f A compound of Embodiment 25b wherein R 2 is 6-chloro-3 -pyridinyl or 2-chloro-5-thiazolyl.
• Embodiment 26g A compound of Formula 1 or any one of Embodiments 1- 26f
• Embodiment 27a A compound of Embodiment 27 where each R 4 and R 5 is
• Embodiment 27b A compound of Embodiment 27a where each R 4 and R 5 is
• Embodiment 27c A compound of Embodiment 27b where each R 4 and R 5 is
• Embodiment 27d A compound of Embodiment 27c wherein each R 4 and R 5 is
• Embodiment 27e A compound of Formula 1 or any one of Embodiments l-27d
• each R 5 is H.
• Embodiment 27f A compound of Embodiment 27e wherein each R 4 and R 5 is H.
• Embodiment 28 A compound of Formula 1 or any one of Embodiments l-27f wherein each R 6 , R 7 and R 8 is independently H, C 1 -C 6 alkyl, C 2 -C 6 alkylcarbonyl or
• Embodiment 29 A compound of Embodiment 28 wherein each R 6 , R 7 and R 8 is
• Embodiment 30 A compound of Formula 1 or any one of Embodiments 1-29 wherein each Z 1 is a direct bond.
• Embodiment 30a A compound of Formula 1 or any one of Embodiments 1-29 wherein each Z 1 is independently a direct bond or O.
• Embodiment 31 A compound of Formula 1 or any one of Embodiments 1-30 wherein each R 16 is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 4 -C 8 alkylcycloalkyl, C 4 -C 8 cycloalkylalkyl, each unsubstituted or substituted with at least one substituent independently selected from the group consisting of halogen, cyano, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 1 -C 4 alkylthio, C 1 -C 4 haloalkylthio, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 6 alkoxycarbonyl, C 2 -C 6 alkylcarbonyloxy and C 3 -Cg dialkylaminocarbonyl.
• Embodiment 33 A compound of Formula 1 or any one of Embodiments 1-32 wherein each R 24 is independently H, cyano, C 1 -C 4 alkyl or C 1 -C 4 alkoxy.
• Embodiment 35 A compound of Formula 1 or any one of Embodiments 1-34 wherein each Qi and Q* is independently phenyl or pyridinyl, each optionally substituted with up to 5 substituents independently selected from halogen and C 1 -C 4 haloalkyl.
• Embodiment 35a A compound of Formula 1 or any one of Embodiments 1-34
• Embodiment 36 A compound of Formula 1 or any one of Embodiments 1-34 wherein each Q t is independently phenyl, pyridinyl or pyrimidinyl, each optionally substituted with up to 5 substituents independently selected from the group consisting of halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy and C 1 -C 4 haloalkoxy.
• Embodiments of this invention can be combined in any manner, and the descriptions of variables in the embodiments pertain not only to the compounds of Formula 1 but also to the starting compounds and intermediate compounds useful for preparing the compounds of Formula 1.
• embodiments of this invention including Embodiments 1-36 above as well as any other embodiments described herein, and any combination thereof, pertain to the compositions and methods of the present invention.
• Embodiment A A compound of Formula 1 wherein
• X is O
• Y is O
• each ring or ring system optionally substituted with up to 5 substituents independently selected from R 15 ;
• R 3a , R 3 ⁇ , R 3c are independently H or halogen
• haloalkylcycloalkyl C 4 -C 8 cycloalkylalkyl, C 4 -C 8 halocycloalkylalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 2 -C 6 alkoxycarbonyl, C 2 -C 6 haloalkoxycarbonyl, C 2 -C 6 alkylcarbonyl and C 2 -C 6 haloalkylcarbonyl;
• R 3 ⁇ s C 1 -C 4 alkyl
• R 4 and R 5 are H;
• a 1.
• Embodiment Al A compound of Embodiment A wherein R 3d is independently halogen, C 1 -C 8 alkyl or C 1 -C 8 alkoxy; or
• haloalkylcycloalkyl C 4 -C 8 cycloalkylalkyl, C 4 -C 8 halocycloalkylalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 2 -C 6 alkoxycarbonyl, C 2 -C 6 haloalkoxycarbonyl, C 2 -C 6 alkylcarbonyl and C 2 -C 6 haloalkylcarbonyl.
• Embodiment B A compound of Embodiment Al wherein
• R 1 is phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with up to 3 substituents independently selected from R 14 ;
• R 21 is C 1 -C 4 alkyl
• R 22 is C 1 -C 4 alkyl
• Z is a direct bond
• each Z 1 is independently a direct bond or O
• each Q 1 is independently phenyl or a 5- or 6-membered heteroaromatic ring
• Embodiment Bl A compound of Embodiment B wherein
• R 1 is phenyl optionally substituted with up to 3 substituents independently selected from R 14 ;
• R 14 is halogen, cyano, SF 5 , CHO, C(O)R 18 , C(O)OR 18 , C(O)NR 21 R 19 , Z 1 Q* or Z 1 Q 1 Z 1 Q t ; or C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 10 cycloalkyl, C 4 -C 10 alkylcycloalkyl, C 4 -C 10 cycloalkylalkyl, C 1 -C 8 alkoxy, C 3 -C 8 cycloalkoxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 8 alkenyloxy, C 2 -C 8 alkynyloxy, C 1 -C 8 alkylthio, C 1 -C 8 alkylsulf ⁇ nyl, C 1 -C 8 alkylsulfonyl, C 3 -C 8
• cycloalkylthio C 4 -C 10 cycloalkylalkylthio, C 2 -C 8 alkenylthio or C 2 -C 8 alkynylthio, each unsubstituted or substituted with at least one substituent independently selected from R 17a ;
• R 17a is halogen, OR 11 or Z 1 Q t ;
• R 2 is pyridinyl, pyrimidinyl or thiazolyl, each optionally substituted with up to 3
• each Z 1 is a direct bond
• each Qi and Q t is independently phenyl or pyridinyl, each optionally substituted with up to 5 substituents independently selected from the group consisting of halogen and C 1 -C 4 haloalkyl.
• Embodiment C A compound of Embodiment Bl wherein
• Z is a direct bond
• R 14 is halogen or Z 1 Q t ; or C 1 -C 8 alkyl, C 1 -C 8 alkoxy or C 1 -C 8 alkylthio, each
• R 2 is pyridinyl, pyrimidinyl or thiazolyl, each optionally substituted with up to 3
• Embodiment D A compound of Embodiment C wherein
• R 3a , R 3b and R 3c are H;
• R 3(1 is halogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxy.
• Embodiment E A compound of Embodiment A wherein
• R 1 is phenyl or a 6-membered heteroaromatic ring, each optionally substituted with up to 3 substituents independently selected from R 14 ;
• R 21 is C 1 -C 4 alkyl
• R 22 is C 1 -C 4 alkyl
• Z is a direct bond
• each Z 1 is a direct bond.
• Embodiment F A compound of Embodiment B wherein R 2 is pyridinyl, pyrimidinyl, oxazolyl or thiazolyl, each optionally substituted with up to 3 substituents independently selected from the group consisting of halogen and C 1 -C 4 alkyl.
• Embodiment G A compound of Embodiment F wherein
• R 1 is phenyl or pyridinyl, each optionally substituted with up to 3 substituents
• each Q* is independently phenyl, pyridinyl or pyrimidinyl, each optionally substituted with up to 5 substituents independently selected from the group consisting of halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy and C 1 -C 4 haloalkoxy.
• Embodiment H A compound of Embodiment G wherein
• R 3a , R 3b and R 3c are H;
• R 3 d is halogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxy.
• Specific embodiments include compounds of Formula 1 selected from the group consisting of:
• An embodiment of this invention is directed to compounds of Formula 1 (including all stereoisomers), iV-oxides, and salts thereof, and compositions containing them and their use for controlling invertebrate pests:
• X is O or S
• Y is O or S
• X I is O, S or NR 9 ;
• E is O, S or NR 9a ;
• R 3a , R 3 b, R 3c and R 3(1 are independently H, halogen, cyano, hydroxy, amino, nitro,
• haloalkylcycloalkyl C 4 -C 8 cycloalkylalkyl, C 4 -C 8 halocycloalkylalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 2 -C 6 alkoxycarbonyl, C 2 -C 6 haloalkoxycarbonyl,
• each R 4 and R 5 is independently H, halogen, cyano, hydroxy, amino, nitro, OCN,
• each R 6 , R 7 and R 8 is independently H; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6
• each R 9 is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8
• cycloalkylcycloalkyl C 5 -C 10 alkylcycloalkylalkyl, C 3 -C 6 cycloalkenyl, C 2 -C 6 alkylcarbonyl or C 2 -C 6 alkoxycarbonyl, each unsubstituted or substituted with at least one substituent independently selected from the group consisting of halogen, cyano, nitro, CHO, C(O)OH, C(O)NH 2 , C(O)R 10 , C(O)OR 11 , C(O)NR 12 R 13 , OR 11 , S(O) n R 10 , SO 2 NR 12 R 13 and Si(R 10 ) 3 ;
• each R 9a is independently H; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 4 -C 8 alkylcycloalkyl, C 4 -C 8 cycloalkylalkyl, C 6 -C 10
• cycloalkylcycloalkyl C 5 -C 10 alkylcycloalkylalkyl, C 3 -C 6 cycloalkenyl, C 2 -C 6 alkylcarbonyl or C 2 -C 6 alkoxycarbonyl, each unsubstituted or substituted with at least one substituent independently selected from the group consisting of halogen, cyano, nitro, CHO, C(O)OH, C(O)NH 2 , C(O)R 10 , C(O)OR 11 ,
• each R 10 , R 11 , R 12 and R 13 is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6
• haloalkylsulf ⁇ nyl C 1 -C 4 haloalkylsulfonyl, C 1 -C 4 alkylamino, C 2 -Cg dialkylamino, C 3 -C 6 cycloalkylamino, C 2 -C 4 alkoxyalkyl, C 2 -C 4
• alkylcarbonyl C 2 -C 6 alkoxycarbonyl, C 2 -C 6 alkylcarbonyloxy, C 2 -C 6 alkylcarbonylthio, C 2 -C 6 alkylaminocarbonyl, C 3 -Cg dialkylaminocarbonyl and C 3 -C 6 trialkylsilyl; or phenyl or a 5- or 6-membered heteroaromatic ring, each unsubstituted or substituted with at least one substituent independently selected from the group consisting Of C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 - C 6 alkynyl, C 3 -C 8 cycloalkyl, C 4 -C 8 alkylcycloalkyl, C 4 -C 8 cycloalkylalkyl, C 6 -C 10 cycloalkylcycloalkyl, C 5 -C 1Q alkyl
• NR 21 NR 21 C( X 2 )NR 22 R 23 , NR 21 NR 21 SO 2 NR 22 R 23 , Z 1 Q t or Z 1 Q 1 Z 1 Q t ; or C 1 - C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 10 cycloalkyl, C 4 -C 10
• alkylcycloalkyl C 4 -C 10 cycloalkylalkyl, C 6 -C 14 cycloalkylcycloalkyl, C 5 -C 10 alkylcycloalkylalkyl, C 3 -C 8 cycloalkenyl, C 1 -C 8 alkoxy, C 3 -C 8 cycloalkoxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 8 alkenyloxy, C 2 -C 8 alkynyloxy, C 1 -C 8 alkylthio, C 1 -C 8 alkylsulfmyl, C 1 -C 8 alkylsulfonyl, C 3 -C 8 cycloalkylthio, C 3 - C 8 cycloalkylsulfinyl, C 3 -C 8 cycloalkylsulfonyl, C 4 -C 10 cycloalkylalkylthio, C 4
• each X 2 is independently O or S;
• each Q 1 is independently a 3- to 10-membered ring or a 7- to 11-membered ring
• each R 15 is independently halogen, cyano, hydroxy, amino, nitro, SF 5 , OCN, SCN,
• each R 16 is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8
• haloalkylsulfonyl C 1 -C 4 alkylamino, C 2 -Cg dialkylamino, C 3 -C 6
• haloalkylsulfinyl C 1 -C 4 haloalkylsulfonyl, C 1 -C 4 alkylamino, C 2 -C 8 dialkylamino, C 3 -C 6 cycloalkylamino, C 2 -C 4 alkoxyalkyl, C 2 -C 4
• alkylcarbonyl C 2 -C 6 alkoxycarbonyl, C 2 -C 6 alkylcarbonyloxy, C 2 -C 6 alkylcarbonylthio, C 2 -C 6 alkylaminocarbonyl, C 3 -C 8 dialkylaminocarbonyl and C 3 -C 6 trialkylsilyl;
• each R 18 , R l 9 and R 20 is independently Q t ; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 4 -C 8 alkylcycloalkyl, C 4 -C 8 cycloalkylalkyl, C 6 - C 10 cycloalkylcycloalkyl, C 5 -C 10 alkylcycloalkylalkyl or C 3 -C 6 cycloalkenyl, each unsubstituted or substituted with at least one substituent independently selected from R 17 ;
• each R 21 , R 22 and R 23 is independently Q t or H; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 - C 6 alkynyl, C 3 -C 8 cycloalkyl, C 4 -C 8 alkylcycloalkyl, C 4 -C 8 cycloalkylalkyl, C 6 -C 10 cycloalkylcycloalkyl, C 5 -C 10 alkylcycloalkylalkyl or C 3 -C 6
• each R 24 is independently H, cyano, OCN, SCN, CHO, C(O)OH, C(O)NH 2 ,
• a 1, 2 or 3;
• each n is independently 0, 1 or 2;
• R 3a or R 3b is other than H.
• compounds of this invention are characterized by favorable metabolic and/or soil residual patterns and exhibit activity controlling a spectrum of agronomic and nonagronomic invertebrate pests.
• compositions comprising a compound of any of the preceding Embodiments, as well as any other embodiments described herein, and any combinations thereof, and at least one additional component selected from the group consisting of a surfactant, a solid diluent and a liquid diluent, said compositions optionally further comprising at least one additional biologically active compound or agent.
• compositions for controlling an invertebrate pest comprising a compound (i.e. in a biologically effective amount) of any of the preceding Embodiments, as well as any other embodiments described herein, and any combinations thereof, and at least one additional component selected from the group consisting of a surfactant, a solid diluent and a liquid diluent, said compositions optionally further comprising at least one additional biologically active compound or agent (i.e. in a biologically effective amount).
• Embodiments of the invention also include a composition for protecting an animal comprising a compound (i.e. in a parasiticidally effective amount) of any of the preceding Embodiments and a carrier.
• Embodiments of the invention further include methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of any of the preceding Embodiments (e.g., as a composition described herein).
• a method for protecting an animal comprising administering to the animal a parasiticidally effective amount of a compound of any of the preceding Embodiments (e.g., as a composition described herein).
• Embodiments of the invention also include a composition comprising a compound of any of the preceding Embodiments in the form of a soil drench liquid formulation.
• Embodiments of the invention further include methods for controlling an invertebrate pest comprising contacting the soil with a liquid composition as a soil drench comprising a biologically effective amount of a compound of any of the preceding Embodiments.
• Embodiments of the invention also include a spray composition for controlling an invertebrate pest comprising a compound (i.e. in a biologically effective amount) of any of the preceding Embodiments and a propellant.
• Embodiments of the invention further include a bait composition for controlling an invertebrate pest comprising a compound (i.e. in a biologically effective amount) of any of the preceding Embodiments, one or more food materials, optionally an attractant, and optionally a humectant.
• Embodiments of the invention also include a device for controlling an invertebrate pest comprising said bait composition and a housing adapted to receive said bait composition, wherein the housing has at least one opening sized to permit the invertebrate pest to pass through the opening so the invertebrate pest can gain access to said bait composition from a location outside the housing, and wherein the housing is further adapted to be placed in or near a locus of potential or known activity for the invertebrate pest.
• Embodiments of the invention also include a method for protecting a seed from an invertebrate pest comprising contacting the seed with a biologically effective amount of a compound of any of the preceding Embodiments (e.g., as a composition described herein).
• Embodiments of the invention also include methods for protecting an animal from an invertebrate parasitic pest comprising administering to the animal a parasiticidally effective amount of a compound of any of the preceding Embodiments.
• Embodiments of the invention also include methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of Formula 1, an JV-oxide, or a salt thereof, (e.g., as a composition described herein), provided that the methods are not methods of medical treatment of a human or animal body by therapy.
• This invention also relates to such methods wherein the invertebrate pest or its environment is contacted with a composition comprising a biologically effective amount of a compound of Formula 1, an JV-oxide, or a salt thereof, and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, said composition optionally further comprising a biologically effective amount of at least one additional biologically active compound or agent, provided that the methods are not methods of medical treatment of a human or animal body by therapy.
• Compounds of Formula Ia can be prepared by condensation of appropriately substituted compounds of Formula 2 with optionally substituted malonic acids (3a) in the presence of condensing agents as shown in Scheme 1.
• Condensing agents can be carbodiimides such as dicyclohexyl carbodiimide (see, for example, Koch, A. et al. Tetrahedron 2004, 60, 10011-10018) or other agents well known in the art to form amide bonds with or without activating agents such as JV-hydroxybenzotriazole as described in Science of Synthesis 2005, 21, 17-25 and Tetrahedron 2005, 61, 10827-10852.
• This reaction is typically carried out in an inert organic solvent, such as dichloromethane or 1 ,2-dichloroethane, at temperatures from about 0 to about 80 0 C for a period of 10 min to several days.
• Compounds of Formula Ia can also be prepared by the condensation of compounds of Formula 2 with malonic acid esters (3b) wherein R is a C 1 -C 5 alkyl group as shown in Scheme 2. These reactions can be performed neat or in the presence of inert solvents as described in Bulletin of the Chemical Society of Japan 1999, 72(3), 503-509. Inert solvents include, but are not limited to, high boiling hydrocarbons such as mesitylene, tetralin or cymene, or high boiling ethers such as diphenyl ether. Typical temperatures range from 50 to 250 0 C. Of note are temperatures from 150 to 200 0 C, which typically provide rapid reaction times and high yields. These reactions can also be performed in microwave reactors within the same temperature ranges. Typical reaction times range from 5 minutes to several hours.
• Compounds of Formula 3a can be prepared by a variety of methods known in the art, for example by base hydrolysis of compounds of Formula 3b.
• Compounds of Formula 3b wherein Z is a direct bond and R 1 is an optionally substituted aromatic (including heteroaromatic) ring or ring system can be prepared by arylation of malonate esters (using compounds of formula R 1 X 1 wherein X 1 is Cl, Br or I, examples of which are found in Tables I-24a-24c) catalyzed by palladium (J. Org. Chem 2002, 67, 541-555) or copper (Org. Lett. 2002, 4, 269-272 and Org. Lett. 2005, 7, 4693- 4695).
• compounds of Formula 3b can be prepared by the method shown in Scheme 2a (see, for example, J. Med. Chem 1982, 25(6), 745-747).
• Esters of Formula 4 can be prepared from the corresponding acids by methods well known in the art. Many of the acids of Formula 4 where R is H are commercially available or readily prepared by methods known in the art (examples are listed in Table 1-1).
• Compounds of Formula 3b can also be prepared by the method shown in Scheme 2b. Reaction of nitriles of Formula 3g with dialkyl carbonates yields nitrile esters of Formula 3h, and subsequent acidic hydrolysis in the presence of an alcohol provides the compounds of Formula 3b (see, for example, Helvetica Chimica Acta 1991, 74(2), 309-314). Many of the nitriles of Formula 3g are commercially available or readily prepared by methods known in the art.
• R is C 1 -C 5 alkyl
• LvO is an activated leaving group as shown in Scheme 3.
• Lv preferred for ease of synthesis or reactivity are phenyl, 4-nitrophenyl or halogen-substituted phenyl (e.g., 2,4,6-trichlorophenyl, pentachlorophenyl or pentafluorophenyl) as described in Archiv der Pharmazie (Weinheim, Germany) 1991, 324, 863-866.
• Other activated esters are well known in the art and include, but are not limited to, jV-hydroxysuccinimide esters (see, for example, J. Am. Chem. Soc. 2002, 124, 6872-6878).
• Typical temperatures range from 50 to 200 0 C. Of note are temperatures from 50 to 150 0 C, which typically provide rapid reaction times and high yields. These reactions can be performed with or without solvent, such as toluene, and in microwave reactors within the same temperature ranges. Typical reaction times range from 5 minutes to 2 hours.
• Compounds of the Formula 3c can be prepared, for example, from compounds of Formula 3a (see, for example, J. Het. Chem. 1980, 17, 337).
• Compounds of Formula Ia can also be prepared by condensation of compounds of
• Compounds of Formula Ib (i.e. Formula Ia wherein Z is a direct bond and R 1 is H) can be prepared by condensation of compounds of Formula 2 with carbon suboxide (3f) (see, for example, J. Org. Chem. 1972, 37(9), 1422-1425) as shown in Scheme 5.
• the reactions are typically performed in an inert solvent such as ether and can include the use of a catalyst such as AlCl 3 .
• Compounds of Formula 2 can be prepared in a variety of ways known in the art; see, for example, Patai, S. The Chemistry of Functional Groups: The Chemistry of Amidines and Imidates; Wiley: Chichester, UK, 1975; The Chemistry of Amidines and Imidates; Patai, S.; Rappoport, Z., Eds.; Wiley: Chichester, UK, 1991; Vol. 2; Mega, T. et al. Bulletin of the Chemical Society of Japan 1988, 61(12), 4315-4321; Ife, R. et al. European Journal of Medicinal Chemistry 1989, 24(3), 249-257; Wagaw, S.; Buchwald, S.
• Compounds of Formula Ia wherein Z is a direct bond and R 1 is C 2 ⁇ Cg alkenyl or an optionally substituted aromatic ring or ring system can be prepared from compounds of Formula Ic (i.e. Formula 1 wherein X and Y are O, Z is a direct bond and R 1 is Cl, Br or I, preferably Br or I) and compounds of Formula 5 wherein R 1 is C 2 ⁇ Cg alkenyl or an optionally substituted aromatic ring or ring system, and M with Z-R 1 forms a boronic acid, boronic acid ester or trifluoroborate salt, or M is trialkylstannyl or zinc and Z is a direct bond, as shown in Scheme 6.
• compounds of Formula 1 wherein a substituent e.g., R 1 or R 2
• a substituent e.g., R 1 or R 2
• a substituent e.g., R 1 or R 2
• a substituent e.g., R 1 or R 2
• a substituent e.g., R 1 or R 2
• a substituent e.g., R 1 or R 2
• a substituent e.g., R 1 or R 2
• two directly bonded aromatic rings or ring systems e.g., a phenyl ring bonded to a second phenyl ring, a phenyl ring bonded to a pyridinyl ring, or a pyridinyl ring bonded to a second pyridinyl ring
• R a is CO 2 R, and R b is CO 2 R, CN or H; or
• R a is CN, and R b is H;
• R is C 1 -C 5 alkyl
• Examples of palladium-containing compounds and complexes useful as catalysts in the methods include PdCl 2 (PPh 3 ) 2 (bis(triphenylphosphine)palladium (II) dichloride), Pd(PPh 3 ) 4 (tetrakis(triphenylphosphine)- palladium(O)), Pd ⁇ HyC ⁇ (palladium(II) acetylacetonate), Pd 2 (dba) 3 (tris(dibenzylidene- acetone)dipalladium(O)), and [1,1 '-bis(diphenylphosphino)ferrocene]dichloropalladium(II).
• PdCl 2 (PPh 3 ) 2 bis(triphenylphosphine)palladium (II) dichloride
• Pd(PPh 3 ) 4 tetrakis(triphenylphosphine)- palladium(O)
• the palladium catalyst preferably has good solubility in the liquid phase.
• Useful solvents include, for example, water, ethers such as 1 ,2-dimethoxyethane, amides such as ⁇ iV-dimethylacetamide, and non-halogenated aromatic hydrocarbons such as toluene.
• the coupling methods can be conducted over a wide range of temperatures, ranging from about 25 to about 200 0 C. Of note are temperatures from about 60 to about 150 0 C, which typically provide fast reaction times and high product yields.
• the general methods and procedures for Stille, Negishi and Suzuki couplings with aryl iodides, bromides or chlorides and an aryl tin, aryl zinc or aryl boronic acid respectively are well known in the literature; see, for example, E. Negishi, Handbook of Organopalladium Chemistry for Organic Synthesis, Wiley-Interscience, 2002, New York, New York.
• the copper catalysts used for the present method typically comprise copper in metallic form (e.g., as a powder) or copper in a formal oxidation state of 1 (i.e. Cu(I)).
• copper-containing compounds useful as catalysts in the method of Scheme 7 include Cu, CuI, CuBr, CuCl.
• Examples of palladium- containing compounds useful as catalysts in the method of Scheme 7 include Pd(O Ac) 2 -
• Useful solvents for the method of Scheme 7 include, for example, ethers such as 1,4- dioxane, amides such as JV,iV-dimethylacetamide and dimethyl sulfoxide.
• the method of Scheme 7 can be conducted over a wide range of temperatures from 25 to 200 0 C. Of note are temperatures from 40 to 150 0 C.
• the method of Scheme 7 can be conducted in the presence of a ligand.
• a wide variety of copper-binding compounds are useful as ligands for the present method. Examples of useful ligands include, but are not limited to, 1,10-phenanthroline, N, ⁇ /-dimethylethylenediamine, L-proline and 2-picolinic acid.
• the general methods and procedures for copper-catalyzed Ullmann-type coupling reactions are well known in the literature; see, for example, Xie, Ma, et al. Org. Lett. 2005, 7, 4693-4695.
• a Lewis acid catalyst e.g., FeC ⁇
• Examples of compounds of Formula 7 useful in the method of Scheme 8 include, but are not limited to, sulfenyl and sulfonyl halides, carboxylic acids, acid anhydrides, acid halides, chloro formates, aminocarbonyl halides, isocyanates and isothiocyanates.
• the reaction is performed in an inert solvent, more typically a polar solvent such as JV,iV-dimethylacetamide or l-methyl-2-pyrrolidinone.
• the reaction is typically performed at temperatures from 0 to 180 0 C, more typically at ambient temperature to 150 0 C. Microwave irradiation can be advantageous in heating the reaction mixture.
• Compounds of Formula Ic can be prepared from compounds of Formula Ib by halogenation using, for example, liquid bromine or JV-halosuccinimides (10) as shown in Scheme 11.
• the reaction is performed in an inert solvent, more typically a halogenated solvent such as methylene chloride or 1,2-dichloroethane.
• the reaction is typically performed at temperatures from 0 to 80 0 C, more typically at ambient temperature.
• Compounds of Formula Ia can also be prepared by alkylation of compounds of Formula 11 using appropriately substituted alkylating agents and bases such as potassium carbonate as shown in Scheme 12 (see, for example, Kappe, T. et al. Monatschefte fur Chemie 1971, 102, 412-424 and Urban, M. G.; Arnold,W. Helvetica Chimica Acta 1970, 53, 905-922).
• Alkylating agents include, but are not limited to, alkyl chlorides, bromides, iodides and sulfonate esters.
• bases and solvents can be employed in the method of Scheme 12, and these bases and solvents are well known in the art.
• Compounds of Formula 11 can be prepared from compounds of Formula 2a by methods analogous to those shown in Schemes 1 through 5 wherein the compound of Formula 2 is replaced by a compound of Formula 2a.
• Compounds of Formula 2a are commercially available or can be prepared by general methods well known in the art.
• Scheme 13 A particularly useful method for the preparation of compounds of Formula 2 is shown in Scheme 13.
• compounds of Formula 2a are protected with suitable protecting groups such as, but not limited to, te/t-butoxycarbonyl, acetyl or formyl to form the intermediate of Formula 2b wherein PG is a protecting group.
• the compound of Formula 2b is then alkylated with an appropriate reagent of Formula 12 (wherein at least one of R 4 or R 5 is hydrogen and X is a leaving group such as a halogen) to give an intermediate of Formula 2c.
• the protecting group is removed to provide a compound of Formula 2.
• Conditions for the formation and removal of protecting groups on an amine function are known in the literature (see, for example, Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991).
• An alternative method for the preparation of compounds of Formula 2 is by the reductive amination of appropriate carbonyl compounds. This method is shown in Steps B and C of Synthesis Example 1, and Step A of Synthesis Example 5.
• Another alternative method for the preparation of compounds of Formula 2 is by the reaction of appropriately substituted amines with halogen-substituted heteroaromatic compounds analogous to the compounds of Formula 2a (i.e. compounds of Formula 2a wherein the amino group is replaced with halogen) in the presence of a copper or palladium catalyst. This method is shown in Step A of Synthesis Example 2.
• Compounds of Formula 2 can also be prepared in a variety of ways known in the art; see, for example, Patai, S. The Chemistry of Functional Groups: The Chemistry of Amidines and Imidates; Wiley: Chichester, UK, 1975; The Chemistry of Amidines and Imidates; Patai, S.; Rappoport, Z., Eds.; Wiley: Chichester, UK, 1991; Vol. 2; Mega, T. et al. Bulletin of the Chemical Society of Japan 1988, 61(12), 4315-4321; Ife, R. et al. European Journal of Medicinal Chemistry 1989, 24(3), 249-257; Wagaw, S.; Buchwald, S.
• Compounds of Formula Ia wherein Z is O can be prepared by reaction of appropriately substituted alcohols (e.g., alkyl alcohols or phenols) with compounds of Formula Ic in the presence of a Cu source (the Ullmann reaction; for example, see Hayashi, S.; Nakanishi, W. Bulletin of the Chemical Society of Japan 2008, 57(12), 1605-1615).
• This Cu-catalyzed reaction is typically performed at room temperature to 200 0 C, more typically at 100 to 150 0 C, and in a solvent such as ⁇ /, ⁇ /-dimethylformamide or N- methylpyrrolidinone.
• this method can be performed in the presence of a Pd source (for example, see Buchwald, S. et al.
• This Pd- catalyzed reaction is typically performed at room temperature to 200 0 C, more typically at 100 to 150 0 C, and in the presence of a base such as K 3 PO 4 , and in the presence of a ligand such as 2-di-fert-butylphosphino-2',4',6'-triisopropylbiphenyl (i.e. di-t-BuXphos) in an inert solvent such as toluene.
• a base such as K 3 PO 4
• a ligand such as 2-di-fert-butylphosphino-2',4',6'-triisopropylbiphenyl (i.e. di-t-BuXphos) in an inert solvent such as toluene.
• Compounds of Formula Ia wherein Z is NR 6 can be prepared by reaction of appropriately substituted amines (e.g., alkyl amines or anilines) with compounds of Formula Ic in the presence of a Cu source (the Ullmann reaction; for example, see Xu, H.; Yin, K.; Huang, W. Chemistry - A European Journal 2007, 75(36), 10281-10293).
• This Cu- catalyzed reaction is typically performed at room temperature to 200 0 C, more typically at 100 to 150 0 C, and in a solvent such as ⁇ /, ⁇ /-dimethylformamide or JV-methylpyrrolidinone.
• this method can be performed in the presence of a Pd source (for example, see Uchiyama, M.
• This Pd-catalyzed reaction is typically performed at room temperature to 200 0 C, more typically at 100 to 150 0 C, in an inert solvent such as toluene, and in the presence of a base such as NaO-t-Bu.
• Compounds of Formula 1 wherein X and/or Y are S can be prepared from corresponding compounds of Formula Ia by general methods known in the art involving treatment with thionating reagents such as P 4 S ⁇ Q or Lawessen's Reagent (2,4-bis-(4- methoxyphenyl)-l,3-dithia-2,4-diphosphetane 2,4-disulf ⁇ de).
• thionating reagents such as P 4 S ⁇ Q or Lawessen's Reagent (2,4-bis-(4- methoxyphenyl)-l,3-dithia-2,4-diphosphetane 2,4-disulf ⁇ de).
• malonic acids of Formula 3a can be treated with P 2 S 6 (CH 3 ) 2 as described in J. Am. Chem. Soc. 1988, 110 (4), 1316-1318.
• the resulting malonic acid sulfur derivatives can then be used to prepare the compounds of Formula 1 wherein X and/
• Schemes 1 through 13 illustrate methods to prepare compounds of Formula 1 having a variety of substituents noted for R 1 , R 2 , R 3a , R 3b , R 4 , R 5 , X, Y, Z and A.
• Compounds of Formula 1 having R 1 , R 2 , R 3a , R 3b , R 4 , R 5 , X, Y, Z and A substituents other than those particularly noted for Schemes 1 through 13 can be prepared by general methods known in the art of synthetic organic chemistry, including methods analogous to those described for Schemes 1 to 13.
• R x is C(O)OH; R ⁇ is H; R a is F; R b , R c and R e are H
• R x is C(O)OH; R ⁇ is H; R b is I; R a , R c and R e are H
• Table 1-2 is identical to Table 1-1, except that R x is C(O)OMe.
• Table 1-3 is identical to Table 1-1, except that R x is C(O)OEt.
• Table 1-4 is identical to Table 1-1, except that R x is C(O)OPh. TABLE 1-5
• Table 1-5 is identical to Table 1-1, except that R x is C(O)OC(CH 3 ) 3 .
• Table 1-5 is identical to Table 1-1, except that R x is C(O)O(2,4,6-trichlorophenyl).
• Table 1-5 is identical to Table 1-1, except that R x is C(O)O(4-nitrophenyl).
• Table 1-6 is identical to Table 1-1, except that R x is C(O)OH and RY is C(O)OH.
• Table 1-7 identical to Table 1-1, except that R x is C(O)OH and RY is C(O)OMe.
• Table 1-8 is constructed the same as Table 1-1, except that R x is C(O)OH and RY is C(O)OEt.
• Table 1-9 identical to Table 1-1, except that R x is C(O)OH and RY is C(O)OC(CH 3 ) 3 .
• Table 1-11 is identical to Table 1-1, except that R x is C(O)OPh and RY is C(O)OMe.
• Table 1-12 is identical to Table 1-1, except that R x is C(O)OPh and RY is C(O)OEt.
• Table 1-13 is identical to Table 1-1, except that R x is C(O)OPh and RY is C(O)OC(CH 3 ) 3 .
• Table 1-14 is identical to Table 1-1, except that R x is C(O)OPh and RY is C(O)OPh.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Agronomy & Crop Science (AREA)
• Pest Control & Pesticides (AREA)
• Environmental Sciences (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Dentistry (AREA)
• Plant Pathology (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Toxicology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Fodder In General (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pretreatment Of Seeds And Plants (AREA)
• Catching Or Destruction (AREA)

Priority Applications (27)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=43242986

Family Applications (1)

Country Status (31)

Cited By (38)

Families Citing this family (27)

Citations (55)

Family Cites Families (13)

• 2010
  • 2010-03-08 UA UAA201202420A patent/UA110924C2/uk unknown
  • 2010-07-27 TW TW104112053A patent/TWI558695B/zh active
  • 2010-07-27 TW TW099124775A patent/TWI489944B/zh active
  • 2010-08-03 SI SI201030515T patent/SI2462124T1/sl unknown
  • 2010-08-03 HR HRP20140196AT patent/HRP20140196T1/hr unknown
  • 2010-08-03 ES ES10740817.1T patent/ES2450422T3/es active Active
  • 2010-08-03 CN CN201410100544.5A patent/CN103819470B/zh active Active
  • 2010-08-03 WO PCT/US2010/044274 patent/WO2011017342A2/en not_active Ceased
  • 2010-08-03 PT PT131844193T patent/PT2679583E/pt unknown
  • 2010-08-03 CN CN201080044648.9A patent/CN102548973B/zh active Active
  • 2010-08-03 NZ NZ597598A patent/NZ597598A/xx unknown
  • 2010-08-03 BR BR112012002485-0A patent/BR112012002485B1/pt active IP Right Grant
  • 2010-08-03 EP EP10740817.1A patent/EP2462124B9/en active Active
  • 2010-08-03 CA CA2769245A patent/CA2769245C/en active Active
  • 2010-08-03 US US13/386,065 patent/US8722690B2/en active Active
  • 2010-08-03 PT PT107408171T patent/PT2462124E/pt unknown
  • 2010-08-03 SG SG2012007852A patent/SG178255A1/en unknown
  • 2010-08-03 JP JP2012523705A patent/JP5777619B2/ja active Active
  • 2010-08-03 CN CN201410544868.8A patent/CN104356130A/zh active Pending
  • 2010-08-03 EP EP13184419.3A patent/EP2679583B1/en active Active
  • 2010-08-03 PL PL10740817T patent/PL2462124T3/pl unknown
  • 2010-08-03 PL PL13184419T patent/PL2679583T3/pl unknown
  • 2010-08-03 MX MX2012001662A patent/MX2012001662A/es active IP Right Grant
  • 2010-08-03 KR KR1020127005653A patent/KR101817810B1/ko active Active
  • 2010-08-03 ES ES13184419.3T patent/ES2546888T3/es active Active
  • 2010-08-03 RS RS20140086A patent/RS53171B/sr unknown
  • 2010-08-03 IN IN571DEN2012 patent/IN2012DN00571A/en unknown
  • 2010-08-03 DK DK10740817.1T patent/DK2462124T3/da active
  • 2010-08-03 HU HUE13184419A patent/HUE025492T2/en unknown
  • 2010-08-03 MY MYPI2012000245A patent/MY156034A/en unknown
  • 2010-08-03 DK DK13184419.3T patent/DK2679583T3/en active
  • 2010-08-03 AU AU2010279582A patent/AU2010279582B2/en active Active
  • 2010-08-05 AR ARP100102878A patent/AR077791A1/es active IP Right Grant
  • 2010-08-05 UY UY0001032831A patent/UY32831A/es active IP Right Grant
• 2012
  • 2012-01-16 IL IL217563A patent/IL217563A/en active IP Right Grant
  • 2012-01-20 TN TNP2012000032A patent/TN2012000032A1/en unknown
  • 2012-01-20 ZA ZA2012/00493A patent/ZA201200493B/en unknown
  • 2012-02-03 CL CL2012000284A patent/CL2012000284A1/es unknown
  • 2012-03-02 MA MA34657A patent/MA33560B1/fr unknown
• 2014
  • 2014-03-19 US US14/219,079 patent/US9210932B2/en active Active
  • 2014-11-17 IL IL235745A patent/IL235745A/en active IP Right Grant
• 2015
  • 2015-11-06 US US14/934,336 patent/US9596856B2/en active Active

Patent Citations (56)

Non-Patent Citations (31)

Also Published As

Similar Documents

Legal Events